EA200971003A1 - Бициклическое соединение и его фармацевтическое применение - Google Patents

Бициклическое соединение и его фармацевтическое применение

Info

Publication number
EA200971003A1
EA200971003A1 EA200971003A EA200971003A EA200971003A1 EA 200971003 A1 EA200971003 A1 EA 200971003A1 EA 200971003 A EA200971003 A EA 200971003A EA 200971003 A EA200971003 A EA 200971003A EA 200971003 A1 EA200971003 A1 EA 200971003A1
Authority
EA
Eurasian Patent Office
Prior art keywords
substituent
optionally containing
group optionally
ring
bicyclic compound
Prior art date
Application number
EA200971003A
Other languages
English (en)
Inventor
Тацуки Койке
Такафуми Такаи
Ясутака Хоаси
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA200971003A1 publication Critical patent/EA200971003A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Настоящее изобретение обеспечивает соединение, представленное формулойгде Rпредставляет собой углеводородную группу, необязательно содержащую заместитель (заместители), аминогруппу, необязательно содержащую заместитель (заместители), гидроксигруппу, необязательно содержащую заместитель, или гетероциклическую группу, необязательно содержащую заместитель (заместители); Rпредставляет собой атом водорода или углеводородную группу, необязательно содержащую заместитель (заместители); Xa и Xb, каждый, представляют собой С, N, O или S; Xc и Xd, каждый, представляют собой С или N; m имеет значение 0-2; n имеет значение 1-3; кольцо А представляет собой 5-членное кольцо, необязательно содержащее заместитель (заместители); кольцо В представляет собой 6-членное кольцо, необязательно содержащее заместитель (заместители); и кольцо С представляет собой 3-5-членное кольцо, необязательно содержащее заместитель (заместители), при условии, что, когда Ха, Хс и Xd, каждый, представляют собой С, тогда Xb представляет собой N или S, или его соль, которое является полезным в качестве средства для профилактики или лечения заболевания, связанного с действием мелатонина, и подобных.
EA200971003A 2007-04-26 2008-04-25 Бициклическое соединение и его фармацевтическое применение EA200971003A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007117676 2007-04-26
PCT/JP2008/058020 WO2008136382A1 (ja) 2007-04-26 2008-04-25 二環性化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
EA200971003A1 true EA200971003A1 (ru) 2010-04-30

Family

ID=39943491

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971003A EA200971003A1 (ru) 2007-04-26 2008-04-25 Бициклическое соединение и его фармацевтическое применение

Country Status (17)

Country Link
US (1) US8110585B2 (ru)
EP (1) EP2141150B1 (ru)
JP (1) JP5289308B2 (ru)
KR (1) KR20100017297A (ru)
CN (1) CN101687810A (ru)
AU (1) AU2008246719A1 (ru)
BR (1) BRPI0810997A2 (ru)
CA (1) CA2684703A1 (ru)
CR (1) CR11084A (ru)
DO (1) DOP2009000250A (ru)
EA (1) EA200971003A1 (ru)
EC (1) ECSP099759A (ru)
IL (1) IL201597A0 (ru)
MA (1) MA31386B1 (ru)
MX (1) MX2009011511A (ru)
TN (1) TN2009000434A1 (ru)
WO (1) WO2008136382A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085367B (zh) * 2014-05-03 2019-05-21 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
KR20180100627A (ko) 2016-01-08 2018-09-11 다케다 야쿠힌 고교 가부시키가이샤 섬망의 예방 또는 치료제
WO2017119455A1 (ja) 2016-01-08 2017-07-13 武田薬品工業株式会社 自閉症スペクトラム障害の予防または治療剤
WO2021131569A1 (ja) * 2019-12-25 2021-07-01 サントリーホールディングス株式会社 睡眠改善用組成物及び概日リズム改善用組成物
CN114137105B (zh) * 2021-11-15 2024-01-19 北京奶牛中心 液相色谱串联质谱法分析样品中褪黑素含量的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
NZ330656A (en) 1996-03-08 1999-06-29 Takeda Chemical Industries Ltd Tricyclic compounds, their production and use
US5981572A (en) 1996-05-14 1999-11-09 Glaxo Wellcome Inc. Benzofurans and benzopyrans as chronobiological agents
RU2190609C2 (ru) 1996-12-10 2002-10-10 Бристол-Маерс Сквибб Компани Производные бензодиоксола, бензофурана, дигидробензофурана и бензодиоксана и содержащие их композиции
US6050506A (en) * 1998-02-13 2000-04-18 Applied Materials, Inc. Pattern of apertures in a showerhead for chemical vapor deposition
CA2334299A1 (en) 1998-06-05 1999-12-09 Pierre Dextraze Heterocyclic cis cyclopropane derivatives as melatonergic agents
PT1189900E (pt) * 1999-06-30 2004-05-31 Bristol Myers Squibb Co Derivados de aminopirrolidina heterociclicos utilizados como agentes melatonergicos
AU2002314744A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
US6569894B1 (en) * 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
AU2003235442A1 (en) 2002-04-12 2003-10-27 Sepracor, Inc. 3-aza- and 1,4-diaza-bicyclo(4.3.0)nonanes, and methods of use thereof
WO2004037250A1 (en) 2002-10-23 2004-05-06 Beyond Genomics, Inc. 4-alkenylthiazoles comprising epoxide functionality, and methods of use thereof
FR2866886B1 (fr) 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
ATE503756T1 (de) 2005-09-29 2011-04-15 Glaxo Group Ltd Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren
JP4793912B2 (ja) 2005-10-31 2011-10-12 サミー株式会社 弾球遊技機
CN101622230B (zh) 2007-02-26 2012-08-22 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物

Also Published As

Publication number Publication date
DOP2009000250A (es) 2010-10-15
US8110585B2 (en) 2012-02-07
CA2684703A1 (en) 2008-11-13
KR20100017297A (ko) 2010-02-16
EP2141150A4 (en) 2011-03-30
EP2141150B1 (en) 2013-12-11
BRPI0810997A2 (pt) 2015-01-27
ECSP099759A (es) 2009-12-28
CR11084A (es) 2010-01-21
WO2008136382A1 (ja) 2008-11-13
EP2141150A1 (en) 2010-01-06
JP5289308B2 (ja) 2013-09-11
AU2008246719A1 (en) 2008-11-13
IL201597A0 (en) 2010-05-31
US20100130538A1 (en) 2010-05-27
JPWO2008136382A1 (ja) 2010-07-29
MA31386B1 (fr) 2010-05-03
MX2009011511A (es) 2009-11-12
TN2009000434A1 (en) 2011-03-31
CN101687810A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
EA200801041A1 (ru) Ингибиторы мек и способы их применения
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201100447A1 (ru) Органические соединения
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
CR10250A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
MA31889B1 (fr) N-phenyl -bipyrrolidine-urees substituees et utilisation therapeutique de celles-ci
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
EA200971003A1 (ru) Бициклическое соединение и его фармацевтическое применение
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
EA200970642A1 (ru) Трициклическое соединение и его фармацевтическое применение
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
EA201290229A1 (ru) Производные спиролактама и их применение
NO20080937L (no) Substituerte-3-sulfonylindazolderivater som 5-hydroksytryptamin-6-ligander
EA200970555A1 (ru) Трициклическое соединение и его медицинское применение